GSK plc (GSK) Stock Analysis

GSK’s competitive edge rests on a combination of product-specific moats and operational scale, but is narrower and more time-bound than some global peers.

The company’s most defensible advantage is its vaccines franchise, anchored by Shingrix (shingles) and Arexvy (RSV). Shingrix generated £3.6 billion in 2025, with high barriers to entry due to proprietary adjuvant technology, manufacturing complexity, and established regulatory approvals. In adult vaccines, GSK’s global scale and supply reliability are valued by public health buyers, giving it an edge over smaller firms and newer entrants like Moderna.

In specialty medicines, GSK’s ViiV Healthcare joint venture is a global leader in HIV, with £7.7 billion in 2025 sales. Long-acting injectables (Cabenuva, Apretude) have shifted the market away from daily oral regimens, creating switching costs and patient loyalty. However, patent cliffs—such as dolutegravir’s expiry in 2027—pose medium-term risks, and Gilead remains a formidable competitor in HIV.

GSK’s scale in manufacturing, regulatory expertise, and global distribution underpin its ability to launch and supply complex biologics and vaccines. Its R&D productivity is improving but still lags innovation leaders like AstraZeneca and Merck. The company’s culture emphasizes scientific rigor and responsible commercialization, supporting trust with regulators and payers.

Overall, GSK’s edge is strongest in vaccines and HIV, with defensible but not unassailable positions. Its future moat depends on continued pipeline renewal and execution in specialty categories.